These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18819118)

  • 1. Bayesian fitting of a logistic dose-response curve with numerically derived priors.
    Huson LW; Kinnersley N
    Pharm Stat; 2009; 8(4):279-86. PubMed ID: 18819118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios.
    Yin G; Li Y; Ji Y
    Biometrics; 2006 Sep; 62(3):777-84. PubMed ID: 16984320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.
    Tighiouart M; Rogatko A; Babb JS
    Stat Med; 2005 Jul; 24(14):2183-96. PubMed ID: 15909291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian nonparametric estimation of continuous monotone functions with applications to dose-response analysis.
    Bornkamp B; Ickstadt K
    Biometrics; 2009 Mar; 65(1):198-205. PubMed ID: 18510655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.
    Wang M; Day R
    J Biopharm Stat; 2010 Jan; 20(1):125-44. PubMed ID: 20077253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
    Zohar S; Chevret S
    J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit.
    Whitehead J; Zhou Y; Stevens J; Blakey G; Price J; Leadbetter J
    Stat Med; 2006 Jan; 25(1):37-53. PubMed ID: 16342336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-objective designs in a dose-response experiment.
    Zhu W; Wong WK
    J Biopharm Stat; 2000 Feb; 10(1):1-14. PubMed ID: 10709797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations for using functional uniform prior distributions for dose-response estimation in clinical trials.
    Bornkamp B
    Biom J; 2014 Nov; 56(6):947-62. PubMed ID: 24984691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Model parameterization, prior distributions, and the general time-reversible model in Bayesian phylogenetics.
    Zwickl D; Holder M
    Syst Biol; 2004 Dec; 53(6):877-88. PubMed ID: 15764557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian design for dose-response curves with penalized risk.
    Sun D; Tsutakawa RK
    Biometrics; 1997 Dec; 53(4):1262-73. PubMed ID: 9423248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
    Mayo MS; Gajewski BJ
    Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
    Bekele BN; Shen Y
    Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian approach to a logistic regression model with incomplete information.
    Choi T; Schervish MJ; Schmitt KA; Small MJ
    Biometrics; 2008 Jun; 64(2):424-30. PubMed ID: 17764482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A parallel phase I/II clinical trial design for combination therapies.
    Huang X; Biswas S; Oki Y; Issa JP; Berry DA
    Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Bayesian approach to bioequivalence for the 2 x 2 changeover design.
    Selwyn MR; Dempster AP; Hall NR
    Biometrics; 1981 Mar; 37(1):11-21. PubMed ID: 7018605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.